Y Gwasanaeth Iechyd Gwladol, Cymru Enwi a dod i rym 1 Enw’r Rheoliadau hyn yw Rheoliadau’r Gwasanaeth Iechyd Gwladol (Contractau Gwasanaethau Meddygol Cyffredinol) (Rhagnodi Cyffuriau Etc.) (Cymru) (Diwygio) 2024 a deuant i rym ar 19 Gorffennaf 2024. Diwygio Rheoliadau’r Gwasanaeth Iechyd Gwladol (Contractau Gwasanaethau Meddygol Cyffredinol) (Rhagnodi Cyffuriau Etc.) (Cymru) 2004 2 1 Mae Atodlen 2 i Reoliadau’r Gwasanaeth Iechyd Gwladol (Contractau Gwasanaethau Meddygol Cyffredinol) (Rhagnodi Cyffuriau Etc.) (Cymru) 2004 wedi ei diwygio fel a ganlyn. 2 Yn y tabl— a yng ngholofn 1 o’r tabl ( cyffuriau ), yn y lle priodol mewnosoder “GnRH analogue”; b yng ngholofn 2 ( claf ), yn y lle priodol mewnosoder— 1 Any patient who is aged 18 or over. 2 Any patient who is aged under 18 to whom the general medical practitioner is providing treatment under the contract which does not include treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. 3 Any patient who is aged under 18, and who— a before 19 July 2024, started a course of treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both, and in this context, a person is treated as having started a course of treatment with a GnRH analogue if, on or after 3 December 2023, that person was issued with a NHS or private prescription for a GnRH analogue, whether or not the prescription has been dispensed or the prescribed GnRH analogue has been taken by that person before 19 July 2024; or b is being treated with a GnRH analogue as part of a National Institute for Health and Care Research clinical trial related to treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. ; c yng ngholofn 3 ( cyflwr ), yn y lle priodol mewnosoder— 1 Treatment for any purpose. 2 Treatment for any purpose other than treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. 3 Treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. ; d yng ngholofn 1 ( cyffuriau ), hepgorer y cofnod ar gyfer “Cyanocobalamin Tablets” a’r rhan gyfagos sy’n ymwneud â’r disgrifiad o’r claf (colofn 2) a’r cyflwr (colofn 3). 3 Ar ddiwedd y tabl, yn y ddarpariaeth ddehongli, yn y lle priodol mewnosoder— “ general medical practitioner ” means a medical practitioner whose name is included in the General Practitioner Register, kept by the General Medical Council under section 2 of the Medical Act 1983 ; “ GnRH analogue ” means gonadotrophin-releasing hormone, a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin; . 4 Ar ddiwedd y tabl, yn y ddarpariaeth ddehongli, yn y diffiniad o “patient”, yn lle “National Health Services (General Medical Services Contracts) (Wales) Regulations 2004” rhodder “National Health Services (General Medical Services Contracts) (Wales) Regulations 2023 ”. Eluned Morgan Ysgrifennydd y Cabinet dros Iechyd a Gofal Cymdeithasol, un o Weinidogion Cymru 27 Mehefin 2024